Low-dose formoterol Turbuhaler® (Oxis®) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.)  by Ekström, T. et al.
RESPIRATORY MEDICINE (1998) 92, 1040-1045 
Low-dose formoterol Turbuhaler @ (Ox@) b.i.d., 
a S-month placebo-controlled comparison with 
terbutaline (q.i.d.) 
T. EKSTR~M*, N. RINGDAL+, V. SOBRADILLO*, E RUNNERSTROM AND S. SOLIMAN’ 
“Department of Respiratory Disease, University Hospital, S-581 85 Linktiping, Sweden 
‘Molde Indremedicinske Kontor, Strandgatan 3, N-6400 Molde, Norway 
*Servicio de Neumologia, Hospital de Cruces, E-48903 Baracaldo, Spain 
‘Astra Dmco AB, Box 34, 221 00 Lund, Sweden 
This study compared the efficacy of a low dose of formoterol Turbuhaler’@ 6,~~g b.i.d. (F) with that of terbutaline 
0.5 mg q.i.d. (T), and placebo (P) from Turbuhalerm. After a 2-week run-in, 397 adults with mild to moderate 
asthma were randomly allocated to one of the treatments for 12 weeks. 
During run-in, the mean morning peak expiratory flow (PEF) was 360 (F), 368 (T) and 367 1 min - i (P). F was 
better than T (P=O.O14) and P (P=O.OOOl) in improving morning PEF [mean changes from run-in: 20 (F), 9 (T), and 
2 1 min ~ ’ (P)]. F was statistically significantly more effective than either T or P in reducing asthma symptoms. F 
gave also statistically significantly higher evening PEF and less use of rescue medication than P. Bronchodilator 
response to study drugs and additional 1.25 mg terbutaline was similar before and after the 12-week treatment 
period. There were no adverse effects of clinical relevance. 
In conclusion, formoterol Turbuhaler, 6 pg b.i.d. was more effective in improving PEF and offered better asthma 
control than either terbutaline Turbuhaler, 0.5 mg q.i.d. or placebo. Regular use of formoterol did not reduce the 
bronchodilator response to additional terbutaline. There were no clinically relevant adverse effects. 
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Introduction 
Current guidelines for management of asthma (1,2) recom- 
mend short-acting &agonists on demand for symptom 
relief, and long-acting &-agonists for regular treatment. 
However, for long-term use, it is of great importance to use 
the lowest dose that gives sufficient control of asthma. 
Formoterol is a relatively new long-acting &agonist. In 
in vitro studies, formoterol has been shown to be about 30 
times more potent than salbutamol in relaxing bronchial 
smooth muscle and at least as &selective as salbutamol 
and terbutaline (3). Formoterol inhaled via pressurized 
metered dose inhaler (pMD1) has been studied extensively 
in man, where the most commonly used doses for patients 
with asthma have been 12pg and 24,ug b.i.d. (46). Oxis@ 
Turbuhaler@ is a new dry powder formulation of for- 
moterol fumarate (hereafter referred to as formoterol) 
developed to combine the favourable pharmacodynamic 
properties of a long-acting &agonist with the user 
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convenience and beneficial drug deposition achieved by 
Turbuhaler. It is therefore possible that low doses can 
achieve sufficient effect when Turbuhaler is used as opposed 
to a pMD1. The effect of formoterol via Turbuhaler has 
been evaluated in a number of studies in adults with asthma 
(7-9). This 12-week placebo-controlled study was under- 
taken to compare the clinical efficacy of formoterol 6,~g 
(delivered dose 4.5 pug) b.i.d. via Turbuhaler and terbutaline 
sulphate, hereafter referred to as terbutaline (0.5 mg q.i.d.) 
via Turbuhaler. Moreover, we aimed at investigating if 
the long-term regular use of &-agonists has a negative 
impact on the immediate response to inhaled long- and 
short-acting &agonist. 
Methods 
PATIENTS 
Three hundred and ninety-seven adult patients (232 men) 
with asthma, according to the ATS definition (lo), recruited 
at 25 centres in Sweden, Norway, Spain and Italy, were 
randomized into the study. Table 1 describes the patients’ 
characteristics. To be included, the patients had to have a 
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TABLE 1. Patient characteristics, baseline lung function tests and daily steroid dose 
Formoterol 6 pg Terbutaline 0.5 mg Placebo 
b.i.d. q.i.d. q.i.d. 
n 
Sex (F/M) 
Age (years) 
mean 
range 
Baseline FEV,% of pred. 
mean 
range 
Reversibility % 
mean* 
range 
Range of daily steroid dose 
No steroids 
<400 pg 
4001800,ug 
800-1200 ,Ug 
>12oo,Ug 
135 133 129 
56158 68148 55/58 
49 46 48 
18-75 2&76 20-79 
62 63 62 
40-97 40-86 40-8 1 
24 25 25 
15-69 1 l-85 13-59 
13% 14% 15% 
5% 3% 6% 
8% 10% 5% 
52% 50% 51% 
22% 23% 23% 
*Measured 15 min after inhalation of 0.5 mg terbutaline sulphate. 
baseline forced expiratory volume in 1 s (FEV,) of 40-80% 
of predicted normal value and they had to show an increase 
of FEV, of 2 15% and at least 200 ml, measured after 
inhalation of 0.5 mg terbutaline via Turbuhaler. Ten 
patients deviated from these criteria but were included in 
the all-patients-treated analyses presented here. 
Prior to the study, 86% of the patients were on inhaled 
corticosteroids; only 5% used sodium cromoglycate 
and 78% used inhaled j&-agonists. Inhaled cortico- 
steroids and sodium cromoglycate were maintained at the 
same dose 4 weeks prior to and throughout the 
study. Terbutaline 0.25 mg via Turbuhaler was used as 
rescue medication, however, the patients were asked 
to avoid inhalation within 6 h prior to the peak expiratory 
flow (PEF) measurements at home and prior to each 
clinic visit. 
STUDY DESIGN 
The study was performed as a parallel-group, double-blind 
trial starting with a 2-week single-blind run-in period 
during which the patients received placebo (lactose) via 
Turbuhaler four times daily and terbutaline via Turbuhaler 
(0.25 mg/inhalation) as rescue medication. The patients 
who completed the run-in period were randomly allocated 
to one of the following treatments: (i) formoterol (Oxis@) 
6pg (corresponding to a delivered formoterol dose of 
4.5,~g) inhaled b.i.d., at 7 a.m. and 7 p.m. and placebo 
(inhaled at 1 p.m. and around 10 p.m.), (ii) terbutaline 
(BricanylCm) 0.5 mg q.i.d. or (iii) placebo q.i.d. inhaled at 
7 a.m., 1 p.m., 7 p.m. and around 10 p.m. All treatments 
were given via Turbuhaler for 12 weeks. Patients in all 
groups received the same number of inhalers which looked 
identical and they were instructed to take the same number 
of inhalations at the scheduled times each day. 
The patients received thorough instruction and practised 
the use of Turbuhaler at the enrolment visit and at the end 
of the run-in period before the allocation of the study 
drugs. Throughout the study, the patients used diary cards 
for recording PEF, asthma symptoms and adverse events. 
During the randomized treatment period, the patients 
attended the clinic after 4, 8 and 12 weeks for assessments 
of lung function. 
EFFICACY 
Pulmonary function 
PEF was measured by the patients every day before inha- 
lation of the study drugs in the morning, i.e. 12 h after 
inhalation of formoterol and 9 h after terbutaline and 
placebo, and in the evening, using a Mini-Wright@ peak 
flow meter. The best of three measurements was recorded 
in the patients’ diary. FEV, was measured at all the clinic 
visits in the morning between 7 and 10 a.m., before 
inhalation of the morning dose of the study medication. 
The highest value of three attempts was recorded 
(Vitalograph @ MDI-compact). At the end of the run-in 
period, FEV, was also measured, 15 min after the inhala- 
tion of formoterol Turbuhaler 6pg. A third FEV, was 
measured 15 min after additional inhalation of 1.25 mg 
terbutaline from Turbuhaler. This procedure was repeated 
at the end of the treatment period to test the impact of 
3 months’ regular formoterol treatment on the maximal 
bronchodilator response. 
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Asthma symptoms and rescue medication 
Combined symptoms (breathlessness, chest tightness, 
wheeze, cough with or without sputum) were scored twice 
daily on a scale from 0 to 3 (O=no symptoms; 1 =mild, 
aware of symptom which is easily tolerated; 2=moderate, 
discomfort enough to cause interference with daily life/ 
usual activity; 3 = severe, incapacitating with inability to 
work or to take part in usual activity). The daily use of 
rescue medication was recorded by the patients in the 
morning and the evening before inhalation of the study 
drug. 
SAFETY 
Blood pressure and pulse were measured at each clinic visit. 
The adverse events were assessed by asking the patients if 
they had experienced any health problems or symptoms not 
usually associated with their asthma. 
STATISTICS 
Assuming a standard deviation of change in morning PEF 
of 50lmin-‘, a sample size of 100 patients in each group 
would give 80% probability to detect a true mean difference 
of 20lmin-’ between the treatment groups. A pairwise 
comparison and a two-tailed significance level of 5% were 
used. 
For each patient, mean PEF values over the run-in 
period and the treatment period were calculated. The 
treatment value was based on the mean over 4-week periods 
and the last-value-extended principle was applied. An 
analysis of variance (ANOVA) model, including the factors 
treatment and centre, was applied. Run-in values were used 
as co-variates. Treatment by centre and treatment by time 
interaction were also investigated. 
Results 
EFFICACY 
Pulmonary function 
PEF. The mean changes in PEF from run-in to each of 
the 4-week periods was consistently higher in the for- 
moterol group than in the terbutaline and placebo groups 
(Fig. 1). Mean PEF values are listed in Table 2. In the 
morning, mean PEF over the 1Zweek treatment increased 
from run-in (mean f SD) by 20 f 35 1 min - ‘, 9 f 45 1 min - ’ 
and 2f261min-’ after formoterol, terbutaline and 
placebo, respectively. The changes in the evening were 
17f331miK’, 9+441min-’ and 2*251min-‘. The 
difference between formoterol and placebo was statistically 
significant in the morning and evening. The difference 
between formoterol and terbutaline was statistically sig- 
nificant only in the morning. Pairwise comparisons are 
presented in Table 3. 
FEV/,. To a great extent, pre-drug FEV, measured every No differences of clinical significance in changes in blood 
4 weeks at the clinic remained at about the same level pressure or pulse were detected between the treatments. 
-10 1 
Baseline 
I 
4 weeks 
I 
8 weeks 12 weeks 
30 
6) 
-10 1 
Baseline 
I I 
4 weeks 8 weeks 
Duration of treatment 
12 weeks 
FIG. 1. Changes from run-in morning (a) and evening (b) 
PEF (1 min- I). ( -) formoterol 6,~g b.i.d. via Turbu- 
haler, (- - -) terbutaline 0.5 mg via Turbuhaler and (. .) 
placebo via Turbuhaler. 
during the study within each treatment. The inhalation of 
6 pg of formoterol caused similar increments of FEV, in all 
groups (Fig. 2), with further increase following additional 
inhalation of terbutaline 1.25 mg from Turbuhaler. The 
bronchodilator responses to formoterol and to additional 
terbutaline were similar after run-in and after 12 weeks of 
treatment in all groups. The maximal increase in FEV, was 
04-0.5 1. 
Asthma symptoms and rescue medication 
Formoterol gave a statistically significantly greater reduc- 
tion in day- and night-time asthma symptoms compared 
with both terbutaline and placebo (Tables 2 and 3). 
Twenty-seven patients discontinued their participation in 
the study due to asthma deterioration: five in the formot- 
erol group, 13 in the terbutaline group and nine in the 
placebo group. 
Formoterol and terbutaline caused a statistically signifi- 
cant reduction in day- and night-time use of rescue medi- 
cation compared with placebo. The difference between 
formoterol and terbutaline in the number of rescue inhala- 
tions was not statistically significant (Tables 2 and 3). 
SAFETY 
TABLE 2. Efficacy variables, mean (SD) of run-in and treatment period 
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Formoterol 6 Terbutaline 0.5 pg mg Placebo 
b.i.d. q.i.d. q.i.d. 
Run-in Treatment Run-in Treatment Run-in Treatment 
PEF 1 min-’ 
morning 360 (96) 380 (95) 368 (97) 377 (99) 367 (113) 370 (117) 
evening 383 (99) 399 (97) 393 (99) 402 (98) 396 (111) 393 (117) 
FEV, (l)* 2.04 (66)* 2.15 (69)t 2.09 (0.71)* 2.10 (0.66)t 2.10 (0.74)* 2.14 (0.71)t 
Asthma symptoms (O-3) 
day 064 (0.55) 0.48 (0.54) 0.77 (0.55) 0.66 (0.55) 0.68 (0.57) 0.63 (0.53) 
night 0.43 (0.47) 0.35 (0.45) 0.66 (055) 0.58 (0.55) 0.49 (0.55) 0.47 (0.50) 
Use of rescue medication 
day 1.14 (1.75) 0.81 (1.22) 1.07 (1.36) 0.91 (1.29) 0.89 (1.22) 1.02 (1.28) 
night 0.51 (0.91) 0.40 (0.67) 0.71 (0.88) 0.69 (1.10) 0.47 (0.79) 0.62 (1.04) 
*Before drug intake at the end of the run-in. 
tMean of values measured after 4, 8 and 12 weeks treatment. 
TABLE 3. Pairwise comparison between treatments in changes from run-in to treatment periods 
Formoterol vs placebo Formoterol vs terbutaline Terbutaline vs placebo 
Diff 95% CI P Diff 95% CI P Diff 95% CI P 
PEF 1 min-’ 
morning 17.6 8.8, 26.5 0~0001 10.9 2.3, 19.5 0.014 6.8 -2.1, 15.6 0.13 
evening 19.0 10.5, 27.3 0.0001 8.0 - 4.0, 16.5 0.061 10.9 2.3, 19.5 0.013 
FEV, l* 0.07 - 0.01, 0.15 0.10 0.13 0.0550.21 0.0017 - 0.06 - 0.14, 0.02 0.13 
Asthma symptoms 
Day-time -0.14 - 0.23, - 0.05 0.0029 -0.09 - 0.18, -0.01 0.038 - 0.05 - 0.13, 0.05 0.35 
Night-time - 0.10 -0.18, -0.01 0.029 - 0.11 - 0.20, - 0.02 0.015 0.01 - 0.08, 0.10 0.81 
Rescue No. of inhal. 
Day-time -0.37 -0.59, -0.15 0.0010 - 0.14 -0.36, 0.08 0.19 - 0.15 - 0.45, - 0.01 0.043 
Night-time -0.23 - 0.39, - 0.07 0.0071 - 0.15 - 0.31, 0.01 0.074 - 0.08 - 0.24, 0.08 0.036 
*Before drug intake in the morning. 
CI, confidence interval. 
Eleven patients (2.7%) discontinued participation in the 
study due to adverse events. There was no difference 
between treatments with regard to the occurrence of 
adverse events. The most frequently occurring adverse 
event was headache experienced by 7% of the patients in the 
formoterol group, 5% in the terbutaline group and 9% in 
the placebo group. 
Asthma aggravation accounted for two serious adverse 
events in the terbutaline group and one serious adverse 
event in the placebo group. 
Discussion 
Studies have demonstrated that a long-term use of the 
inhaled P-agonists formoterol at doses of 12 and 24pg 
(1 l-14) and salmeterol at a dose of 50 lug (15,16) resulted in 
sustained improvement in lung function and control of 
asthma symptoms. 
Despite the well-documented beneficial effect of long- 
term use of long-acting B-agonists, there is a concern that 
such use may have a negative impact on asthma due to the 
development of tolerance to the bronchodilatory or bron- 
choprotective effect of inhaled &agonists (17-19). In this 
context, it is therefore important to find the lowest effective 
dose for long-term regular use. 
This study demonstrated that regular use of 6 pug formot- 
erol Turbuhaler (delivered dose of 4.5 pg) b.i.d. is sufficient 
to obtain good asthma control in terms of improved lung 
function, reduced asthma symptoms and reduced use of 
rescue medication. These results are in accordance with the 
findings in other formoterol studies (4,5,9). 
The magnitude of changes in PEF from run-in to treat- 
ment obtained by 6 pg formoterol Turbuhaler in this study 
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FIG. 2. Mean FEV, measured at the end of run-in and 
after 12 weeks’ treatment. (+), before inhalation and 
(m) after inhalation of formoterol 6,~g, (0) after 
additional inhalation of 1.25 mg terbutaline, both from 
Turbuhaler. 
is comparable with that obtained by 12pg formoterol 
Turbuhaler b.i.d. in a previous study with a similar 
design and in patients with similar characteristics (9). These 
data indicate that it is possible to achieve a sufficient effect 
with half of the dose used in other formoterol studies, 
presumably due to a more effective lung deposition through 
Turbuhaler. Studies with terbutaline and salbutamol have 
shown a higher lung deposition of Turbuhaler compared 
with other devices (20,21). However, these findings do not 
exclude the potential benefit of increasing the dose from 6 
to 12 or 24,~g b.i.d. in some patients. 
In the context of possible negative impact of long-term 
use of formoterol, neither in the present nor in a previous 
study (9), has it been possible to demonstrate any reduction 
in the effect of formoterol Turbuhaler after regular treat- 
ment. The bronchodilatory response to an additional short- 
acting drug was maintained after 3 months of regular 
treatment with formoterol or terbutaline, thus there was 
no development of a clinically relevant, sub-sensitivity of 
the &receptors, in this patient population of whom the 
majority were using inhaled &agonists prior to the 
study. This study, on the other hand, was not designed 
to investigate the problem of reduced bronchoprotective 
effect. 
Formoterol Turbuhaler 6pg b.i.d was well tolerated. The 
incidence and type of adverse events were generally low and 
mild in all treatment groups and there was no evidence of 
drug-related adverse events. 
The present results, together with the earlier 3-month 
formoterol study (9), show that on top of inhaled steroids, 
6 pug may be sufficient as regular treatment in many patients 
with mild to moderate asthma. From the combined evi- 
dence of the safety and efficacy data accumulated in this 
and other comparative trials, we may conclude that for- 
moterol Turbuhaler is an effective bronchodilatory agent 
which is well tolerated and which offers greater benefit in 
the control of asthma than does regular treatment with a 
short-acting &agonist. 
Conclusion 
Formoterol Turbuhaler 6 pg (delivered dose of 4.5 pug) twice 
daily was more efficacious than either terbutaline from 
Turbuhaler 0.5 mg four times daily or placebo in improving 
pre-drug morning PEF and reducing day-time and night- 
time asthma symptoms. There was no evidence of decreased 
bronchodilatory response to formoterol or additional 
terbutaline. All treatments were well tolerated. 
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